November 20, 2018, MedPage Today  

Results of preliminary studies evaluating immune checkpoint inhibitors in ovarian cancer are good, but there are ways to make them better, experts said.

"The first published experience in ovarian cancer shows very promising results and a much higher efficacy than expected from previously known mono-immunotherapeutics like vaccines or immuno-stimulants, but the positive results do not compare with the extraordinary results in other entities like melanoma, where checkpoint inhibition changed the game," said Klaus Pietzner, MD, of Charité-University Medicine in Berlin, and colleagues.